期刊文献+

前列腺癌筛查研究进展

Research Progress on Prostate Cancer Screening
原文传递
导出
摘要 目的:探讨近年来前列腺癌筛查的研究进展和发展趋势。方法:使用Pubmed以及万方等检索工具检索近年来前列腺癌筛查方面的相关文献,总结前列腺癌筛查的最新研究进展及未来发展趋势。结果:为达到切实、有效的诊断目的,从而对筛查的必要性以及更为精准的血清前列腺特异性抗原(PSA)筛查阈值进行了大量研究和探索,同时也对血清PSA衍生物以及其他更具特异性的筛查标记物进行了系列研究和探索。结论:血清PSA及其衍生物虽然应用较为广泛,但因其不具有前列腺癌组织特异性,致使筛查结果存在误差。所以寻找敏感性更高且具有前列腺癌组织特异性的标记物是未来前列腺癌筛查研究的重要趋势之一。 Objective:To systematically investigate recent researches of prostate cancer screening and discuss its future development trend. Methods:To retrieve and summarize the relevant research papers in the area of prostate cancer screening in recent years through Pubmed, Wanfang and other searching tools. The fu- ture development trend of prostate cancer screening researches was discussed. Results: In order to achieve the purpose of practicality and effectivity in clinical diagnostic, plenty of researches were done on the necessity of screening, more accurate serum prostate specific antigen (PSA) screening threshold, and also on serum PSA derivatives and other more specific screening biomarkers. Conclusions:Although serum PSA and its derivativesare widely used in prostate cancer screening, they are not specific expressed in prostate cancer tissues, which can re- sult in the detecting error of prostate cancer screening. Therefore, it suggests that one important development trend of prostate cancer screening can be searching new biomarkers for prostate cancer screening with higher sensitivity and specificity in prostate cancer tissues.
出处 《解剖与临床》 2012年第6期530-533,共4页 Anatomy and Clinics
关键词 前列腺癌 筛查 前列腺特异抗原 标记物 Prostate cancer Screening Prostate specific antigen Biomarkers
  • 相关文献

参考文献36

  • 1Siegel R, Ward E, Brawley O, et al. Cancer statistics, 2011 : the impact of eliminating socioeconomic and racial disparities on prema- ture cancer deaths. CA Cancer J Clin,2011,61 (g) : 212 -236.
  • 2Etzioni R, Gulati R, Falcon S, et al. Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States : a surveillance modeling approach. Med Decis Making,2008,28(3) : 323 - 331.
  • 3Klein EA. What new in prostate cancer screening and prevention? Cleve Clin J Med, 2009,76 ( 8 ) :439 - 445.
  • 4Jayadevappa R, Chhatre S, Weiner M, et al. Medical care cost of patients with prostate cancer. Urol Oncol,2005,23(3) : 155 -162.
  • 5Guh DP, Zhang W, Bansback N, et al. The incidence of co - mor- bidities related to obesity and overweight: a systematic review and meta - analysis. BMC Public Health, 2009,9 : 88 - 108.
  • 6Stamatiou K, Skolarikos A. Rural residence and prostate cancer screening with prostate -specific antigen. Rural Remote Health, 2009,9(2) : 1227.
  • 7Hamashima C, Nakayama T, Sagawa M, et al. The Japanese guide- line for prostate cancer screening. Jpn J Clin Oncol, 2009,39 ( 6 ) : 339 -351.
  • 8Schroder FH, Hugosson J, Roobol M J, et al. Screening and prostate - cancer mortality in a randomized European study. N Engl J Med, 2009,360( 13 ) : 1320 - 1328.
  • 9Hugosson J, Carlsson S, Aus G, et al. Mortality results from the Goteborg randomised population - based prostate - cancer screening trial. Lancet Oncol,2010,11 (8) : 725 - 732.
  • 10Draisma G, Etzioni R, Tsodikov A, et al. Lead time and overdiag- nosis in prostate - specific antigen screening: importance of methods and context. J Natl Cancer Inst,2009,101 (6) : 374 - 383.

二级参考文献13

  • 1翁志梁,余凯远,毛晓露,陶志华,陈晓东,吴秀玲,胡元平,王思齐,李澄棣,陈占国.外周血差异显示编码3mRNA定量检测在前列腺癌患者诊断与治疗监测中的初步应用[J].中华医学杂志,2006,86(41):2911-2915. 被引量:9
  • 2陶志华,毛晓露,王彩虹,陈晓东,余凯远,翁志梁,胡元平,张筱骅,谢辉,王瓯晨,宋其同,李澄棣,陈占国.DD3 mRNA在前列腺癌组织中定量表达分析[J].中华男科学杂志,2007,13(2):130-133. 被引量:15
  • 3Bussemakers M J, van Bokhoven A, Verhaegh GW, et al. DD3:a new prostate specific gene, highly over expressed in prostate cancer. J Cancer Res, 1999, 59 (23) : 5975 -5979.
  • 4Tinzl M,Marberger M, Horvath S, et al. DD3Pca3 RNA analysis in urine- a new perspective for detecting prostate cancer . J Eur Urol, 2004, 46 (2) : 182-186.
  • 5de Kok JB, Verhaegh GW, Roelofs RW, et al. DD3 ( PCA3 ) , a very sensitive and specific marker to detect prostate tumors. J Cancer Res, 2002, 62 (9) : 2695 - 2698.
  • 6Liang P, Pardee AB. Differential display. A general protocol. J Mol Biotechnol ,1998 ,10(3) :261-267.
  • 7Hessels D , Klein Gunnewiek JM , van Oort I , et al. DD3 ( PCA3 ) - based molecular urine analysis for the diagnosis of prostate cancer. J Eur Urol ,2003 ,44(1) :8 -16.
  • 8Fradet Y, Saad F, Ap rikian A, et al. uPM3, a new molecular urine test for the detection of prostate cancer. J Urology, 2004,64 ( 2 ) : 311 -315.
  • 9Thelen P, Burfeind P, GrzmilM, et al. cDNA microarray analysis with amplified RNA after isolation of intact cellular RNA from neoplastic and non - neoplastic prostate tissue separated by laser microdissections. Int J Oncol, 2004, 24 (5) : 1085 - 1092.
  • 10Landers KA, Burger MJ, Tebay MA, et al. Use of multiple biomarkers for a molecular diagnosis of prostate cancer. Int J Cancer, 2005, 114(6) :950 -956.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部